Recombinant human erythropoietin to target cognitive dysfunction in bipolar disorder: a double-blind, randomized, placebo-controlled phase 2 trial : Reply

This item is discarded!Release HistoryDetailsSummary

Recombinant human erythropoietin to target cognitive dysfunction in bipolar disorder: a double-blind, randomized, placebo-controlled phase 2 trial : Reply

Miskowiak, K. W., Ehrenreich, H., Kessing, L. V., & Vinberg, M. (2015). Recombinant human erythropoietin to target cognitive dysfunction in bipolar disorder: a double-blind, randomized, placebo-controlled phase 2 trial: Reply. Journal of Clinical Psychiatry, 76(6), e835-e836. doi:10.4088/JCP.151r09809a.

Item is Discarded

Basic (Discarded)

Date of Discard: 2023-07-21

Comment: Dublette

Creators:
Miskowiak, Kamilla W.
Ehrenreich, Hannelore¹
Kessing, Lars V.
Vinberg, Maj

Affiliations:
1Clinical neuroscience, Max Planck Institute of Experimental Medicine, Max Planck Society, ou_2173651

Dates: Date issued: 2015-06

Files: 1 File

Locators: 0 Locators

version ID: item_2186437_2

Item State: Discarded

Name of Context: Import Context of the MPI of Experimental Medicine, Affiliated to: Max Planck Institute of Experimental Medicine